1
|
Sued O, Ambrosioni J, Nicolás D, Manzardo C, Agüero F, Claramonte X, Plana M, Tuset M, Pumarola T, Gallart T, Gatell JM, Miró JM. Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes. PLoS One 2015; 10:e0131651. [PMID: 26186440 PMCID: PMC4506046 DOI: 10.1371/journal.pone.0131651] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 06/03/2015] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Interventions during primary HIV infection (PHI) can modify the clinical course during the chronic phase. The long-term effect of structured treatment interruptions (STI) followed by low doses of interleukin-2 (IL-2) in treated PHI patients is unknown. METHODS Twelve PHI patients with viral load (VL) <20 copies/mL, CD4 cells >500 cells/mm3, and CD4/CD8 ratio >1, on antiretroviral therapy (ART) initiated within the first 90 days of infection and continued for at least 12 months were included. They underwent four STI and were then allocated (week 0 of the study) to ART alone or ART plus low doses of IL-2. ART was stopped once VL <20 copies/mL ('final stop'). Primary endpoints were VL<3000 copies/mL and CD4 cells >500 cells/mm3 at 48 weeks; secondary endpoints were immune activation, inflammatory markers until 48 weeks and the time before resuming ART (CD4 <350 cells/mm3 or AIDS) after 'final stop', compared between groups. RESULTS Ten out of 12 patients were males, median age was 35 years and the main risk was men-who-have-sex-with-men. Only one out of 12 patients (in the STI group) maintained VL<3000 copies/mL and CD4 cells >500 cells/mm3 without ART at 48 weeks. All other virological and immunological parameters were comparable between groups at week 0, 'final stop' and week 48. However, the proportion of CD8-CD38+ cells, tumor necrosis factor and srIL-2 were higher in the IL-2 group at 'final stop' and week 24. All these differences vanished during follow-up. At 5 years after the final stop 3 out of 6 patients in the IL-2 group and 6 out of 6 patients in the STI group have resumed ART (P = 0.19). CONCLUSIONS STI and IL-2 failed to achieve virological control after ART interruption. STI were not deleterious in long-term follow-up, an important issue for eradication and functional cure trials. TRIAL REGISTRATION ClinicalTrials.gov NCT02300623.
Collapse
Affiliation(s)
- Omar Sued
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Juan Ambrosioni
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - David Nicolás
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Christian Manzardo
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Fernando Agüero
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Xavier Claramonte
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Montserrat Plana
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Montserrat Tuset
- Pharmacy Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Tomás Pumarola
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Teresa Gallart
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - José María Gatell
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
| | - José María Miró
- Infectious Diseases Service, Hospital Clínic–IDIBAPS, University of Barcelona, Barcelona, Spain
- * E-mail:
| |
Collapse
|
2
|
Abstract
Immune-based therapy (IBT) interventions have found a window of opportunity within some limitations of the otherwise successful combined antiretroviral therapy (cART). Two major paradigms drove immunotherapeutic research to combat human immunodeficiency virus (HIV) infection. First, IBTs were proposed either to help restore CD4(+) T-cell counts in cases of therapeutic failures with cytokines, interleukin-2 (IL-2) or IL-7, or to better control HIV and disease progression during treatment interruptions with anti-HIV therapeutic candidate vaccines. The most widely used candidates were HIV-recombinant live vector-based alone or combined with other vaccine compounds and dendritic cell (DC) therapies. A more recent and current paradigm aims at achieving HIV cure by combining IBT with cART using either cytokines to reactivate virus production in latently infected cells and/or therapeutic immunization to boost HIV-specific immunity in a 'shock and kill' strategy. This review summarizes the rationale, hopes, and mechanisms of successes and failures of these cytokine-based and vaccine-based immune interventions. Results from these first series of IBTs have been so far somewhat disappointing in terms of clinical relevance, but have provided lessons that are discussed in light of the future combined strategies to be developed toward an HIV cure.
Collapse
Affiliation(s)
- Guislaine Carcelain
- UPMC Univ Paris 06, UMR-S945, Laboratory of Immunity and Infection, Paris, France
| | | |
Collapse
|
3
|
Pria AD, Hayward K, Bower M. Do we still need chemotherapy for AIDS-associated Kaposi’s sarcoma? Expert Rev Anticancer Ther 2014; 13:203-9. [DOI: 10.1586/era.12.179] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
4
|
Chang CC, Lim A, Omarjee S, Levitz SM, Gosnell BI, Spelman T, Elliott JH, Carr WH, Moosa MYS, Ndung'u T, Lewin SR, French MA. Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis 2013; 208:898-906. [PMID: 23766525 DOI: 10.1093/infdis/jit271] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS) may be driven by aberrant T-cell responses against cryptococci. We investigated this in human immunodeficiency virus (HIV)-infected patients with treated cryptococcal meningitis (CM) commencing combination antiretroviral therapy (cART). METHODS Mitogen- and cryptococcal mannoprotein (CMP)-activated (CD25+CD134+) CD4+ T cells and -induced production of interferon-gamma (IFN-γ), IL-10, and CXCL10 were assessed in whole blood cultures in a prospective study of 106 HIV-CM coinfected patients. RESULTS Patients with paradoxical C-IRIS (n = 27), compared with patients with no neurological deterioration (no ND; n = 63), had lower CMP-induced IFN-γ production in 24-hour cultures pre-cART and 4 weeks post-cART (P = .0437 and .0257, respectively) and lower CMP-activated CD4+ T-cell counts pre-cART (P = .0178). Patients surviving to 24 weeks had higher proportions of mitogen-activated CD4+ T cells and higher CMP-induced CXCL10 and IL-10 production in 24-hour cultures pre-cART than patients not surviving (P = .0053, .0436 and .0319, respectively). C-IRIS was not associated with higher CMP-specific T-cell responses before or during cART. CONCLUSION Greater preservation of T-cell function and higher CMP-induced IL-10 and CXCL10 production before cART are associated with improved survival while on cART. Lower CMP-induced IFN-γ production pre-cART, but not higher CMP-specific T-cell responses after cART, were risk factors for C-IRIS.
Collapse
Affiliation(s)
- Christina C Chang
- Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Kim W, Chung HB, Chung CC. Constant drug dose in human immuno‐deficiency virus‐infected patients to induce long‐term non‐progressor status: bifurcation and controllability approach. IET Syst Biol 2013; 7:79-88. [DOI: 10.1049/iet-syb.2012.0006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Wonhee Kim
- Department of Electrical EngineeringHanyang UniversitySeoul133-791Korea
| | - Han Byul Chung
- Department of Electrical EngineeringHanyang UniversitySeoul133-791Korea
- MANDO Corp.Kyonggi-DoKorea
| | - Chung Choo Chung
- Division of Electrical and Biomedical EngineeringHanyang UniversitySeoul133-791Korea
| |
Collapse
|
6
|
Harari A, Rozot V, Cavassini M, Enders FB, Vigano S, Tapia G, Castro E, Burnet S, Lange J, Moog C, Garin D, Costagliola D, Autran B, Pantaleo G, Bart PA. NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. Eur J Immunol 2012; 42:3038-48. [DOI: 10.1002/eji.201242696] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2012] [Revised: 07/11/2012] [Accepted: 08/15/2012] [Indexed: 01/03/2023]
Affiliation(s)
- Alexandre Harari
- Division of Immunology and Allergy; Lausanne University Hospital; Lausanne Switzerland
- Swiss Vaccine Research Institute; Lausanne Switzerland
| | - Virginie Rozot
- Division of Immunology and Allergy; Lausanne University Hospital; Lausanne Switzerland
| | - Matthias Cavassini
- Division of Infectious Diseases; Lausanne University Hospital; Lausanne Switzerland
| | | | - Selena Vigano
- Division of Immunology and Allergy; Lausanne University Hospital; Lausanne Switzerland
| | - Gonzalo Tapia
- Division of Immunology and Allergy; Lausanne University Hospital; Lausanne Switzerland
| | - Erika Castro
- Division of Immunology and Allergy; Lausanne University Hospital; Lausanne Switzerland
| | - Séverine Burnet
- Division of Immunology and Allergy; Lausanne University Hospital; Lausanne Switzerland
| | - Joep Lange
- Department of Global Health; Academic Medicial Center; Amsterdam Institute for Global Health and Development; University of Amsterdam; The Netherlands
| | - Christiane Moog
- INSERM Unit 748; Université de Strasbourg, Strasbourg, France
| | | | - Dominique Costagliola
- UPMC Université de Paris 06 and INSERM; UMRS 943 Paris France
- Cellular Immunology Laboratory; Pierre and Marie Curie University; INSERM UMRS 543, Pitié-Salpêtrière Hospital; Paris France
| | - Brigitte Autran
- Cellular Immunology Laboratory; Pierre and Marie Curie University; INSERM UMRS 543, Pitié-Salpêtrière Hospital; Paris France
| | - Giuseppe Pantaleo
- Division of Immunology and Allergy; Lausanne University Hospital; Lausanne Switzerland
- Swiss Vaccine Research Institute; Lausanne Switzerland
| | - Pierre-Alexandre Bart
- Division of Immunology and Allergy; Lausanne University Hospital; Lausanne Switzerland
| |
Collapse
|
7
|
Shete A, Thakar M, Singh DP, Gangakhedkar R, Gaikwad A, Pawar J, Paranjape R. Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations. AIDS Res Hum Retroviruses 2012; 28:835-43. [PMID: 21936714 DOI: 10.1089/aid.2010.0363] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Therapeutic vaccinations using human immunodeficiency virus (HIV) antigens in HIV-infected patients on antiretroviral therapy (ART) have so far been attempted with the purpose of inducing CTL response. However, they can also be useful as a strategy for activation of latent HIV reservoir, which is thought to be mainly comprised of latently infected HIV-specific memory CD4 cells, eventually leading to elimination of the virus. The present study was carried out to explore the ability of different HIV antigens to activate HIV replication as assessed by intracellular P24 detection as well as to induce T cell responses in terms of cytokine expression by flow cytometry after stimulation of PBMCs from HIV-infected patients. HIV antigens were found to be able to activate most of the CD4 T cells harboring proviral DNA. HIV-1 Pol and Env were responsible for induction of higher HIV replication in terms of both magnitude and frequency followed by Gag and Nef. As opposed to this, Pol and Env contributed to fewer numbers of polyfunctional CD8 cells desirable for elimination of HIV-infected cells in comparison to Gag and Nef. Thus, HIV antigens may provide a strategy for the activation of a latent reservoir. It was observed that HIV replication started as early as half an hour after in vitro activation indicating a stringent need for maintaining effective concentrations of antiretroviral drugs to prevent further spread of HIV during this process. HIV-infected cells were found to be responsible for higher IL-10 secretion after activation, which could also serve as one of the reasons for suppressed CD8 responses to Pol and Env as more HIV-infected CD4 cells would be secreting IL-10 in response to these antigens. Since IL-10 blockade helped to improve immune responses in terms of cytokine secretion, it should be considered in settings of therapeutic vaccination to improve CTL responses, which will ultimately limit the persistence of the viral reservoir.
Collapse
Affiliation(s)
| | | | | | | | | | - Jyoti Pawar
- National AIDS Research Institute, Pune, India
| | | |
Collapse
|
8
|
García F, León A, Gatell JM, Plana M, Gallart T. Therapeutic vaccines against HIV infection. Hum Vaccin Immunother 2012; 8:569-81. [PMID: 22634436 DOI: 10.4161/hv.19555] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Resistance to medication, adverse effects in the medium-to-long-term and cost all place important limitations on lifelong adherence to combined antiretroviral therapy (cART). In this context, new therapeutic alternatives to 'cART for life' in HIV-infected patients merit investigation. Some data suggest that strong T cell-mediated immunity to HIV can indeed limit virus replication and protect against CD4 depletion and disease progression. The combination of cART with immune therapy to restore and/or boost immune-specific responses to HIV has been proposed, the ultimate aim being to achieve a 'functional cure'. In this scenario, new, induced, HIV-specific immune responses would be able to control viral replication to undetectable levels, mimicking the situation of the minority of patients who control viral replication without treatment and do not progress to AIDS. Classical approaches such as whole inactivated virus or recombinant protein initially proved useful as therapeutic vaccines. Overall, however, the ability of these early vaccines to increase HIV-specific responses was very limited and study results were discouraging, as no consistent immunogenicity was demonstrated and there was no clear impact on viral load. Recent years have seen the development of new approaches based on more innovative vectors such as DNA, recombinant virus or dendritic cells. Most clinical trials of these new vectors have demonstrated their ability to induce HIV-specific immune responses, although they show very limited efficacy in terms of controlling viral replication. However, some preliminary results suggest that dendritic cell-based vaccines are the most promising candidates. To improve the effectiveness of these vaccines, a better understanding of the mechanisms of protection, virological control and immune deterioration is required; without this knowledge, an efficacious therapeutic vaccine will remain elusive.
Collapse
Affiliation(s)
- Felipe García
- Hospital Clinic-HIVACAT, IDIBAPS, University of Barcelona, Barcelona, Spain.
| | | | | | | | | |
Collapse
|
9
|
Zurakowski R. Nonlinear observer output-feedback MPC treatment scheduling for HIV. Biomed Eng Online 2011; 10:40. [PMID: 21619634 PMCID: PMC3127993 DOI: 10.1186/1475-925x-10-40] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2011] [Accepted: 05/27/2011] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Mathematical models of the immune response to the Human Immunodeficiency Virus demonstrate the potential for dynamic schedules of Highly Active Anti-Retroviral Therapy to enhance Cytotoxic Lymphocyte-mediated control of HIV infection. METHODS In previous work we have developed a model predictive control (MPC) based method for determining optimal treatment interruption schedules for this purpose. In this paper, we introduce a nonlinear observer for the HIV-immune response system and an integrated output-feedback MPC approach for implementing the treatment interruption scheduling algorithm using the easily available viral load measurements. We use Monte-Carlo approaches to test robustness of the algorithm. RESULTS The nonlinear observer shows robust state tracking while preserving state positivity both for continuous and discrete measurements. The integrated output-feedback MPC algorithm stabilizes the desired steady-state. Monte-Carlo testing shows significant robustness to modeling error, with 90% success rates in stabilizing the desired steady-state with 15% variance from nominal on all model parameters. CONCLUSIONS The possibility of enhancing immune responsiveness to HIV through dynamic scheduling of treatment is exciting. Output-feedback Model Predictive Control is uniquely well-suited to solutions of these types of problems. The unique constraints of state positivity and very slow sampling are addressable by using a special-purpose nonlinear state estimator, as described in this paper. This shows the possibility of using output-feedback MPC-based algorithms for this purpose.
Collapse
Affiliation(s)
- Ryan Zurakowski
- Department of Electrical and Computer Engineering, University of Delaware, Newark, DE 19716, USA.
| |
Collapse
|
10
|
Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol 2011; 32:131-7. [PMID: 21317040 DOI: 10.1016/j.it.2010.12.002] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2010] [Revised: 12/04/2010] [Accepted: 12/09/2010] [Indexed: 01/26/2023]
Abstract
The introduction of combined antiretroviral therapies (HAART) has reversed the fatal course of human immunodeficiency virus (HIV) infection. HAART controls virus production and, in most cases, allows the quantitative and functional immune defects caused by HIV to be reversed. Here, we review T cell homeostatic mechanisms that drive immune recovery. These homeostatic mechanisms, as well as differences in T cell antigen exposure, explain the distinct patterns of recovery for HIV-specific T cells versus T cells specific for other pathogens. Immune restoration during HAART can, however, have adverse effects. Immune restoration syndrome occurs in some patients as a result of successful but unbalanced immunity.
Collapse
|
11
|
Mestre G, Garcia F, Martinez E, Milinkovic A, Lopez A, León A, Mora B, Argelich R, Lozano JM, Peña J, Gatell JM, Plana M. Short Communication: Natural killer cells and expression of KIR receptors in chronic HIV type 1-infected patients after different strategies of structured therapy interruption. AIDS Res Hum Retroviruses 2008; 24:1485-95. [PMID: 19025397 DOI: 10.1089/aid.2008.0135] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Few data evaluating the NK cell profile during structured therapy interruption (STI) in chronic HIV-1 infection are available. Changes in NK cell percentages and KIR and NKG2A receptors were analyzed at baseline and after 2 years of follow-up in 121 patients on ART with CD4(+) >450 cells/ml and VL <200 copies/ml randomized in three arms according to the criteria employed to resume ART during STI: virological arm (VA n = 47, VL >30,000 copies/ml or CD4 <350 cells/ml), immunological arm (IA n = 37, CD4< 350 cells/ml), and a control arm (n = 37) in which ART was maintained. After 2 years of follow-up, a decrease in CD3(-)CD56(+) CD16(+) cell percentages in VA and IA patients, but not in CA patients, was observed. Those patients with higher decrease in CD3(-)CD56(+)CD16(+) cells had a higher decrease in CD4(+) cells (r = 0.35, p = 0.001) and higher increase in PVL (r = -0.26, p = 0.02). KIR and NKG2A receptor expression tended to increase in CA and decreased in the other two arms (more in IA than in VA). Patients who displayed a greater decrease in CD4(+) T cells and a greater rise in PVL after 2 years of follow-up had a significantly higher decrease in KIR and NKG2A receptors expressed in CD3(-)CD56(+) cells. Patients who presented the lowest levels of total NK cells and KIR and NKG2A receptor expression after STI showed the poorest virology or immunology outcomes. This finding suggests that STI could decrease the number of NK subsets, which is related to the worst clinical development in these patients.
Collapse
Affiliation(s)
- Gabriel Mestre
- Infectious Diseases Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Felipe Garcia
- Infectious Diseases Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- HIV Vaccine Development in Catalonia (HIVACAT), Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Esteban Martinez
- Infectious Diseases Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Ana Milinkovic
- Infectious Diseases Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Anna Lopez
- HIV Vaccine Development in Catalonia (HIVACAT), Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
- Retrovirology and Viral Immunopathology Laboratory, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - Agathe León
- Infectious Diseases Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- HIV Vaccine Development in Catalonia (HIVACAT), Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Borja Mora
- Infectious Diseases Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- HIV Vaccine Development in Catalonia (HIVACAT), Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Roger Argelich
- Infectious Diseases Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- HIV Vaccine Development in Catalonia (HIVACAT), Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - José Manuel Lozano
- Immunology Laboratory, Hospital Reina Sofía, University of Córdoba, Córdoba, Spain
| | - José Peña
- Immunology Laboratory, Hospital Reina Sofía, University of Córdoba, Córdoba, Spain
| | - José M. Gatell
- Infectious Diseases Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- HIV Vaccine Development in Catalonia (HIVACAT), Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Montserrat Plana
- HIV Vaccine Development in Catalonia (HIVACAT), Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
- Retrovirology and Viral Immunopathology Laboratory, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain
| |
Collapse
|
12
|
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008; 22:1313-22. [PMID: 18580611 DOI: 10.1097/qad.0b013e3282fdce94] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVE Evaluate immunogenicity and clinical efficacy of two immunization strategies with the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients. DESIGN Randomized, double-blind, placebo-controlled, phase II study of vCP1452 immunization in chronically HIV-infected patients on therapy with CD4 T-cell count more than 350 cells/microl, CD4 nadir less than 400 cells/microl and pHIV-RNA less than 400 copies/ml. Patients were equally randomized to four injections at weeks 0, 4, 8, 20; three injections at weeks 4, 8, 20; and placebo. The primary endpoint was vaccine immunogenicity at week 24 measured by enzyme-linked immunospot-interferon-gamma against the HIV-gag-reverse transcriptase-nef vaccine sequences. Secondary endpoints included time to treatment resumption and viral quantitation following treatment interruption at week 24. Criteria to resume therapy included CD4 T-cell count decline less than 250 cells/microl or 50% decrease from baseline or pHIV-RNA more than 50,000 copies/ml. RESULTS Sixty-five patients enrolled. Changes from baseline in HIV-specific T cells in the four injection arms (+480 spot-forming cells/M-peripheral blood mononuclear cell) were significant compared to placebo (+8; P = 0.014), but not in the three injection arms (+322). The week 36 pHIV-RNA (log10 copies/ml) after treatment interruption was higher in the four (4.71; P = 0.023) and three (4.82; P = 0.009) injection arms compared to placebo (4.40). Percentages of patients reaching treatment resumption criteria by week 48 were 74, 55 and 23% in the three respective arms (P = 0.013). Two independent factors influenced time to therapy resumption: immunization (hazards ratio = 2.7, P = 0.048 for three injections; hazards ratio = 4.1, P = 0.003 for four injections) and CD4 nadir (hazards ratio = 0.4, P = 0.002). CONCLUSIONS Significant immunogenicity was induced by vCP1452; however, this strategy was independently associated with a shorter time to resume therapy and higher viral rebound.
Collapse
|
13
|
|
14
|
Chang H, Astolfi A. Control of the transition to long-term nonprogressor in tristable HIV dynamics. ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE 2008; 2008:4940-4944. [PMID: 19163825 DOI: 10.1109/iembs.2008.4650322] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The human immunodeficiency virus (HIV) infection, that causes acquired immune deficiency syndrome (AIDS), is a dynamic process that can be modeled via differential equations. In this paper we apply a control strategy to boost the immune response for a tristable HIV dynamic model. The purpose of this control method is to steer the system to an equilibrium condition known as long-term nonprogressor, which corresponds to an infected patient that does not develop the symptoms of AIDS. The control strategy is implemented by controlled drug scheduling based on the understanding of the immune boosting mechanism. The feasibility of the methodology is illustrated via simulations.
Collapse
Affiliation(s)
- H Chang
- Department of Electrical and Electronic Engineering, Imperial College, London SW7 2AZ, UK.
| | | |
Collapse
|
15
|
Chang H, Astolfi A. Leading to long-term nonprogressor via gradual reduction of drug dose with immune dynamics strongly dependant on target cells. ACTA ACUST UNITED AC 2007; 2007:1094-7. [PMID: 18002152 DOI: 10.1109/iembs.2007.4352486] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
For a HIV dynamic model with immune system which strongly depends on the HIV target cells, we apply a recently proposed drug scheduling scheme: gradual reduction of drug dose. The feasibility of this scheme is analysed rigorously. By means of this method, the HIV patient is steered to an equilibrium condition known as long-term nonprogressor, which corresponds to an infected status not developing the symptoms of AIDS.
Collapse
Affiliation(s)
- H Chang
- Department of Electrical and Electronic Engineering, Imperial College, London SW7 2AZ, UK.
| | | |
Collapse
|
16
|
Iglesias MC, Mollier K, Beignon AS, Souque P, Adotevi O, Lemonnier F, Charneau P. Lentiviral Vectors Encoding HIV-1 Polyepitopes Induce Broad CTL Responses In Vivo. Mol Ther 2007; 15:1203-10. [PMID: 17375069 DOI: 10.1038/sj.mt.6300135] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Lentiviral vectors have been tested as vaccination vectors in anti-tumoral and anti-viral models. They efficiently transduce dendritic cells and stimulate strong T-cell responses against the encoded antigen. However, their capacity to stimulate a cytotoxic T-lymphocyte (CTL) response against several antigens has not been evaluated. Broad anti-human immunodeficiency virus 1 (HIV-1) T-cell immune responses are important for the control of HIV replication. We evaluated the potential of polyepitope-encoding lentiviral vectors to induce broad anti-HIV CTL responses. We constructed two lentiviral vectors coding for an HLA-A2- or HLA-B7-restricted polyepitope and evaluated their immunogenicity by direct injection of vector particles in HLA-A2 or HLA-B7 transgenic mice. In vitro cytotoxicity assays showed that a single immunization induces a strong, diversified, and long-lasting CTL response in both mouse models. CTL responses were directed against all 13 epitopes in the HLA-A2 system and 8 out of 12 in the HLA-B7 system. A second immunization augmented the number of responding mice in the HLA-A2 system but not in the HLA-B7 system. HLA-B7-immunized mice mounted strong interferon-gamma (IFN-gamma)-secreting T-cell responses against a majority of the epitopes and lysed peptide-loaded target cells in vivo. CTL responses in HLA-B7 mice were only partially dependent on CD4 T-cell help. This work underlines the potential of lentiviral vectors as candidates for therapeutic vaccination against acquired immunodeficiency syndrome.
Collapse
|
17
|
|
18
|
Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, Dhillon T, Holmes P, Gazzard BG, Stebbing J. Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma. J Clin Oncol 2005; 23:5224-8. [PMID: 16051964 DOI: 10.1200/jco.2005.14.597] [Citation(s) in RCA: 205] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose A proportion of patients with HIV infection who subsequently receive highly active antiretroviral therapy (HAART) exhibit a deterioration in their clinical status, despite control of virologic and immunologic parameters. This clinical response, known as the immune reconstitution inflammatory syndrome (IRIS), occurs secondary to an immune response against previously diagnosed pathogens. Patients and Methods From our cohort of 5,832 patients treated in the HAART era, we identified 150 therapy-naive patients with a first presentation of Kaposi's sarcoma (KS). Their clinicopathologic features and progress were recorded prospectively. Results After commencing HAART, ten patients (6.6%) developed progressive KS, which we identify as IRIS-associated KS. In a comparison of these individuals with those whose KS did not progress, we found that IRIS-KS occurred in patients with higher CD4 counts (P = .03), KS-associated edema (P = .01), and therapy with both protease inhibitors and non-nucleosides together (P = .03). Time to treatment failure was similar for both groups, although the CD4 count declined more rapidly at first, in those patients with IRIS-associated KS. Despite this initial decline, in our clinical experience HAART could be successfully continued in those with IRIS-associated KS. Conclusion We have identified IRIS-KS in a cohort of HIV patients with KS who start HAART.
Collapse
Affiliation(s)
- M Bower
- Department of Oncology, Chelsea and Westminster Hospital, London SW10 9NH, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Zurakowski R, Teel AR. A model predictive control based scheduling method for HIV therapy. J Theor Biol 2005; 238:368-82. [PMID: 15993900 DOI: 10.1016/j.jtbi.2005.05.004] [Citation(s) in RCA: 130] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2004] [Revised: 05/23/2005] [Accepted: 05/24/2005] [Indexed: 11/20/2022]
Abstract
Recently developed models of the interaction of the human immune system and the human immunodeficiency virus (HIV) suggest the possibility of using interruptions of highly active anti-retroviral therapy (HAART) to simulate a therapeutic vaccine and induce cytotoxic lymphocyte (CTL) mediated control of HIV infection. We have developed a model predictive control (MPC) based method for determining optimal treatment interruption schedules for this purpose. This method provides a clinically implementable framework for calculating interruption schedules that are robust to errors due to measurement and patient variations. In this paper, we discuss the medical motivation for this work, introduce the MPC-based method, show simulation results, and discuss future work necessary to implement the method.
Collapse
Affiliation(s)
- Ryan Zurakowski
- Department of Ecology and Evolutionary Biology, 321 Steinhaus Hall, University of California, Irvine, CA 92697, USA.
| | | |
Collapse
|
20
|
Thiébaut R, Pellegrin I, Chêne G, Viallard JF, Fleury H, Moreau JF, Pellegrin JL, Blanco P. Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 x 10(6) cells/l. AIDS 2005; 19:53-61. [PMID: 15627033 DOI: 10.1097/00002030-200501030-00006] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To analyse immunological markers associated with CD4+ lymphocyte T-cell count (CD4+) evolution during 12-month follow-up after treatment discontinuation. METHOD Prospective observational study of chronically HIV-1 infected patients with CD4+ above 400 x 10(6) cells/l. RESULTS CD4+ changes took place in two phases: an initial rapid decrease in the first month (-142 x 10(6) cells/l on average), followed by a slow decline (-17 x 10(6) cells/l on average) The second slope of CD4+ decline was not correlated with the first and only baseline plasma HIV RNA was associated with it. The decline in CD4+ during the first month was steeper in patients with higher CD4+ and weaker plasma HIV RNA baseline levels. Moreover, the decline was less pronounced (P < 10(-4)) in patients with CD4+ nadir above 350 x 10(6) cells/l (-65 x 10(6) cells/l per month) in comparison with those below 350 x 10(6) cells/l (-200 x 10(6) cells/l per month). A high number of dendritic cells (DCs) whatever the type was associated with high CD4+ at the time of treatment interruption and its steeper decline over the first month. Moreover, the myeloid DC level was stable whereas the lymphoid DC count, which tended to decrease in association with decrease in CD4+, was negatively correlated with the HIV RNA load slope. CONCLUSIONS The results support the use of the CD4+ nadir to predict the CD4+ dynamic after treatment interruption and consideration of the CD4+ count after 1-month of interruption merely reflects the 12-month level of CD4+. Although DCs seem to be associated with the CD4+ dynamic, the benefit of monitoring them has still to be defined.
Collapse
Affiliation(s)
- Rodolphe Thiébaut
- INSERM E0338 & U593, ISPED, Université Bordeaux 2, Bordeaux Cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Therapeutic vaccines aim to prevent severe complications of a chronic infection by reinforcing host defenses when some immune control, albeit insufficient, can already be demonstrated and when a conventional antimicrobial therapy either is not available or has limited efficacy. We focus on the rationale and challenges behind this still controversial strategy and provide examples from three major chronic infectious diseases- human immunodeficiency virus, hepatitis B virus, and human papillomavirus-for which the efficacy of therapeutic vaccines is currently being evaluated.
Collapse
Affiliation(s)
- Brigitte Autran
- Laboratoire d'Immunologie Cellulaire and INSERM Unit 543, Centre Hospitalier Universitaire Pitié-Salpétrière, Université Pierre et Marie Curie, 75013 Paris, France.
| | | | | | | |
Collapse
|
22
|
Bernstein WB, Cox JH, Aronson NE, Tracy L, Schlienger K, Ratto-Kim S, Garner R, Cotte J, Zheng Z, Winestone L, Liebig C, Galley LM, Connors M, Birx DL, Carroll RG, Levine BL. Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4+ T cells to HIV-infected persons. Clin Immunol 2004; 111:262-74. [PMID: 15183147 DOI: 10.1016/j.clim.2004.03.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2003] [Accepted: 03/02/2004] [Indexed: 01/09/2023]
Abstract
We have previously shown that adoptive transfer of in vitro CD3/CD28 activated autologous CD4(+) T cells results in increased CD4 counts and CD4/CD8 ratios in HIV+ subjects. In this report, analysis of variable beta (Vbeta) chain T cell receptor (TCR) repertoire showed that CD3/CD28 stimulation was able to increase polyclonality within skewed spectra types in vitro. In vivo, two of eight subjects showed increase in TCR diversity and importantly, in no subject did a highly skewed in vivo repertoire emerge. Measurement of proliferative response to alloantigen showed increases following infusions. Response to pharmacological stimulus and lectin via Interferon-gamma ELISpot assay showed increases in a subset of subjects following infusions. However, interferon-gamma response to HIV antigens and peptides declined concurrent with stable or diminishing latent infectious viral load in CD4(+) T cells. These data provide further evidence that adoptive transfer of activated autologous CD4(+) T cells can augment the immune system.
Collapse
Affiliation(s)
- Wendy B Bernstein
- Division of Retrovirology, Walter Reed Army Institute of Research, Rockville MD 20850, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Affiliation(s)
- A K Sahni
- Associate Professor, Department of Microbiology, Armed Forces Medical College, Pune - 411 040
| | - A Nagendra
- Professor and Head, Department of Microbiology, Armed Forces Medical College, Pune - 411 040
| |
Collapse
|
24
|
Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, Schneider L, Ghosn J, Pauchard M, Costagliola D, Katlama C, Calvez V. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrob Agents Chemother 2004; 48:644-7. [PMID: 14742228 PMCID: PMC321535 DOI: 10.1128/aac.48.2.644-647.2004] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The dynamics of mutations associated with resistance to antiretroviral drugs were analyzed after cessation of therapy. The results showed that the kinetics of the shift to wild-type amino acid residues were significantly faster for protease inhibitors, intermediate for nonnucleoside reverse transcriptase inhibitors, and slower for nucleoside reverse transcriptase inhibitors.
Collapse
Affiliation(s)
- Marc Wirden
- Department of Virology, INSERM EMI 0214, Pitié-Salpêtrière Hospital, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Autran B, Debré P, Walker B, Katlama C. Therapeutic vaccines against HIV need international partnerships. Nat Rev Immunol 2003; 3:503-8. [PMID: 12776210 DOI: 10.1038/nri1107] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The successes of anti-retroviral treatments against HIV are limited today by the cost and toxicity of lifelong administration. An innovative therapeutic strategy has been proposed to boost the immune system of infected patients with HIV vaccines and to help limit the use of anti-retroviral treatments. This perspective article reviews the crucial questions raised by such a strategy and the main international efforts that are already set up to provide rapid answers--in particular, a not-for-profit international network that is dedicated to the development of therapeutic immunization programmes against HIV.
Collapse
Affiliation(s)
- Brigitte Autran
- Laboratoire d'Immunologie Cellulaire, Centre Hospitalier Universitaire Pitié-Salpétrière, 75651 Paris, France.
| | | | | | | |
Collapse
|
26
|
Wendel TD. Immunoengineering: a credible mechanism for CAMPATH-1H action in bone marrow and organ transplantation and the implications for treatment of the immune dysfunction AIDS. Med Hypotheses 2003; 60:360-72. [PMID: 12581613 DOI: 10.1016/s0306-9877(02)00404-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Immunoengineering is a term coined to represent the mostly future ability to use or target the immune system's natural components, with emphasis on the regulatory components, to up or down regulate the immune system's attack against specific proteins associated with an unwanted pathology or immune occurrence. It will constitute manipulating parts of the immune system, mostly those specific for the disease associated antigen(s) and generally of a regulatory nature, in various immunological locale or the whole body compartment, to achieve a disease free state for the patient. The number of practical applications awaiting the mastery of immune components as regulatory therapeutics is enormous and immunoengineering should provide treatments in a wide range of disease categories. HIV is a disease where this discipline could provide a quick cure, even eradication of the virus. A potential cheap solution to HIV infection, based on using immunoengineering and adaptable to the infrastructure problems of the Third World is highlighted in the following because of the health emergency that exists in the Third World.
Collapse
|
27
|
Wendel TD. An editorial for the HIV infected: immune regulation. The implications for treatment of HIV infection and the potential role of T cell suppressor pathways instead of apopstasis, anergy or direct CD4 T cell deletion in AIDS pathogenesis. Med Hypotheses 2003; 60:373-81. [PMID: 12581614 DOI: 10.1016/s0306-9877(02)00405-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The AIDS crises makes for an interesting study of the interactions of activists, researchers, caregivers, the press, politicians and other groups in society. In the popular press and elsewhere there has been a growing movement since the inception of the disease to place efforts against AIDS as the highest standard of our benevolence, proficiency and determination when confronting a disease. Because of the potential benefit in understanding the interactions of groups and how research progressed and failed during the AIDS crises, differing perspectives should be recorded on this matter. The person currently in most need of an objective viewpoint on AIDS research, including an outlook on the past, as well as the present and future, is the person who is infected with HIV. While many of the AIDS related bureaucracies, scientists and celebrities have achieved consecration in the fight against HIV, a question arises whether this praise is deserved and really due to their keeping the AIDS patient as the first matter of the heart and mind; or whether they have merely achieved what bureaucracies and celebrity are best at, making society and those they should serve, think that they cannot do with out them.The following editorial chronicles a scandalous intellectual failure of immunologists in the fight against HIV. It delineates potential areas of concern for the HIV infected patient in the present and future, which may be important directions in the fight against HIV, both for treatment to evolve to the ideal and for an economically viable treatment for the Third World.
Collapse
|
28
|
Trabattoni D, Lo Caputo S, Biasin M, Seminari E, Di Pietro M, Ravasi G, Mazzotta F, Maserati R, Clerici M. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 2002; 9:1114-8. [PMID: 12204968 PMCID: PMC120079 DOI: 10.1128/cdli.9.5.1114-1118.2002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Analysis of the virologic and immunomodulatory effects of an association of efavirenz (EFV), nelfinavir (NFV), and stavudine (d4T) was performed in 18 human immunodeficiency virus (HIV)-infected and highly active antiretroviral therapy (HAART)-experienced patients who failed multiple therapeutic protocols. Patients (<500 CD4(+) cells/ micro l; >10,000 HIV copies/ml) were nonnucleoside reverse transcriptase inhibitor (NNRTI)-naive and were treated for 10 months with EFV (600 mg/day) in association with NFV (750 mg three times daily) and d4T (30 or 40 mg twice daily). Measurement of HIV peptide- and mitogen-stimulated production of interleukin-2 (IL-2), gamma interferon (IFN-gamma), IL-4, and IL-10 as well as quantitation of mRNA for the same cytokines in unstimulated peripheral blood mononuclear cells were performed at baseline and 2 weeks (t1), 2 months (t2), and 10 months (t3) into therapy. The results showed that HIV-specific (but not mitogen-stimulated) IL-2 and IFN-gamma production was augmented and IL-10 production was reduced in patients who received EFV, NFV, and d4T. Therapy was also associated with a reduction in HIV RNA in plasma and an increase in CD4(+) cell count. These changes occurred in the first year of therapy (t2 and t3) and were confirmed by quantitation of cytokine-specific mRNA. Therapy with EFV, NFV, and d4T increases HIV-specific type 1 cytokine production as well as CD4 counts and reduces plasma viremia. This therapeutic regimen may be considered for use in cases of advanced HIV infection.
Collapse
Affiliation(s)
- Daria Trabattoni
- Cattedra di Immunologia, Università di Milano, DISP, LITA Vialba, Milan, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Combadière B, Carcelain G, Debré P, Autran B. Plasticity of lymphoid compartments during HIV infection and treatments: hopes and limits. Microbes Infect 2002; 4:575-80. [PMID: 11959514 DOI: 10.1016/s1286-4579(02)01575-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Immune reconstitution during antiretroviral therapy has recently been shown to depend upon multiple factors at work in T-cell homeostasis, amongst which the reduction of thymus dysfunction and of immune hyperactivation is instrumental. The restoration of host defenses against opportunistic pathogens is, however, balanced by the poor immunity restored against HIV thus giving a satisfying link between antigen stimulation and the reconstitution of immune responses to pathogens.
Collapse
Affiliation(s)
- Béhazine Combadière
- Laboratoire d'Immunologie Cellulaire et Tissulaire, Unité INSERM 543, Hôpital Pitié-Salpétrière, 83, boulevard de l'Hôpital, 75013 Paris, France
| | | | | | | |
Collapse
|
30
|
Abstract
In this review, we address recent advances in the understanding of the pathogenesis of human immunodeficiency type 1 virus infection, which have provided the rationale for present trials of therapeutic vaccines. We shall relate this work to lessons of the past few years both in the use of highly active antiretroviral therapy to attempt eradication of the HIV virus, and in the study of treatment interruptions.
Collapse
Affiliation(s)
- S Kinloch-de Loes
- Department of HIV/Thoracic Medicine, Department of Medicine, The Royal Free Centre for HIV Medicine, Royal Free Campus, Royal Free and University College Medical School, London, NW3 2PF, UK.
| | | |
Collapse
|
31
|
Badley AD, Hawley-Foss N, Mbisa G, Lum JJ, Pilon AA, Angel JB, Garber G. Reply. Clin Infect Dis 2002. [DOI: 10.1086/338018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Affiliation(s)
- Andrew D. Badley
- Division of Infectious Diseases, Ottawa Health Research Institute, Ottawa, Ontario, Canada
- Ottawa Hospital-General Campus, Ottawa, Ontario, Canada
| | - Nanci Hawley-Foss
- Division of Infectious Diseases, Ottawa Health Research Institute, Ottawa, Ontario, Canada
- Ottawa Hospital-General Campus, Ottawa, Ontario, Canada
| | | | - Julian J. Lum
- Ottawa Hospital-General Campus, Ottawa, Ontario, Canada
| | | | - Jonathan B. Angel
- Division of Infectious Diseases, Ottawa Health Research Institute, Ottawa, Ontario, Canada
- Ottawa Hospital-General Campus, Ottawa, Ontario, Canada
| | - Gary Garber
- Division of Infectious Diseases, Ottawa Health Research Institute, Ottawa, Ontario, Canada
| |
Collapse
|
32
|
Potential Adverse Effects of Structured Therapeutic Interruptions on the Pool of HIV-Infected Cells. J Acquir Immune Defic Syndr 2001. [DOI: 10.1097/00126334-200110010-00015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Sonza S, Crowe SM. Reservoirs for HIV infection and their persistence in the face of undetectable viral load. AIDS Patient Care STDS 2001; 15:511-8. [PMID: 11689138 DOI: 10.1089/108729101753205676] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- S Sonza
- AIDS Pathogenesis Research Unit, Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria, Australia
| | | |
Collapse
|
34
|
Abstract
Highly active antiretroviral therapies (HAART) lower morbidity and mortality of HIV infection, but are unable to eradicate HIV and may cause side-effects. Planned interruptions of HAART are studied for three reasons: (1) to stimulate the anti-HIV immune response after viraemia has been suppressed by treatment; (2) to increase time off drug, to improve quality of life and diminish side effects and costs; and (3), among individuals whose virus has become resistant to treatment, to induce reversion of resistance to wild-type and therefore to improve the chances of success of subsequent salvage therapy. Regarding immune stimulation, the most promising results come from rare patients who started HAART during primary HIV infection. Up to 60% controlled viraemia below 5,000 copies/mL for up to 1 year without HAART. Among the majority of patients who start HAART later, during chronic HIV infection, preliminary results suggest that after repeated cycles on and off therapy, about 20% remain with a viraemia below 5,000 copies/mL after 12 weeks' treatment interruption. For the 80% who rebound to higher viraemia, additional immune-stimulatory manoeuvres are being considered such as administration of cytokines, or specific immune treatment by anti-HIV vaccines. When treatment is interrupted in patients who fail HAART and who have drug-resistant HIV, the drug-sensitive wild-type replaces the resistant quasispecies in 30-60% of patients. It remains to be seen whether this phenomenon increases the chances of successful salvage therapy. The risks and benefits of treatment interruption still have to be compared in large clinical trials, which are currently in the planning stage.
Collapse
Affiliation(s)
- B Hirschel
- Division of Infectious Diseases, University Hospital, Geneva, Switzerland.
| |
Collapse
|
35
|
Carcelain G, Debré P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001; 13:483-8. [PMID: 11498306 DOI: 10.1016/s0952-7915(00)00245-4] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Immune reconstitution during antiretroviral therapy has recently been shown to depend upon multiple factors at work in T cell homeostasis, amongst which the reduction of thymus dysfunction and of immune hyperactivation are instrumental. The optimism that has been raised by the restoration of hosts' defenses against opportunistic pathogens is, however, balanced by the poor immunity restored against HIV; thus, innovative immune interventions are required.
Collapse
Affiliation(s)
- G Carcelain
- Laboratoire d'Immunologie Cellulaire et Tissulaire, Unité INSERM 543, Hopital Pitié-Salpétrière, 83 Boulevard de l'Hôpital, 75013, Paris, France
| | | | | |
Collapse
|
36
|
Klein M. Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. Vaccine 2001; 19:2210-5. [PMID: 11257335 DOI: 10.1016/s0264-410x(00)00547-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In spite of extensive prevention programs, the HIV pandemic is still spreading worldwide, particularly in developing countries. AIDS is the leading cause of death in Africa and the fourth cause worldwide. WHO estimates that there are 16000 new cases of HIV infection daily and that 100 million individuals will be infected during the next decade. In spite of the spectacular results of triple therapy, the best strategy for controlling the HIV epidemics remains the development of an efficacious prophylactic vaccine. However, the development of such a vaccine remains a formidable challenge to both the industry and the scientific community (Esparza J. Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 2000; 355: 2061-6 [1]).
Collapse
Affiliation(s)
- M Klein
- Aventis Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
| |
Collapse
|